Cellectis (CLLS) Profit After Tax Growth (1y) (2015 - 2026)
Cellectis (CLLS) Profit After Tax Growth (1y) (2015 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
66.06% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
17.05% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-129.68% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-290.15% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-632.44% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
2.00% |
| Date | Value |
|---|
| Mar 31, 2026 |
2.00% |
| Dec 31, 2025 |
-544.41% |
| Sep 30, 2025 |
3.30% |
| Jun 30, 2025 |
-65.66% |
| Mar 31, 2025 |
-421.25% |
| Dec 31, 2024 |
111.80% |
| Sep 30, 2024 |
26.66% |
| Jun 30, 2024 |
-51.85% |
| Mar 31, 2024 |
117.35% |
| Dec 31, 2023 |
-75.73% |
| Sep 30, 2023 |
-86.14% |
| Jun 30, 2023 |
67.28% |
| Mar 31, 2023 |
-1.92% |
| Dec 31, 2022 |
-1.71% |
| Sep 30, 2022 |
21.98% |
| Jun 30, 2022 |
1.79% |
| Mar 31, 2022 |
-168.88% |
| Dec 31, 2021 |
-160.09% |
| Sep 30, 2021 |
3.69% |
| Jun 30, 2021 |
-323.75% |
